MAPT and Alzheimer disease: To our knowledge, this is the first study to examine the link between SCD and genetic predisposition for Aβ42 and Tau, adding the PRS approach for AD biomarkers and combining it with actual CSF measurements in two different populations in order to replicate the observed results.